Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet  Stephen.

Published by그린 목 Modified over 5 years ago

Similar presentations

Presentation on theme: "Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet  Stephen."— Presentation transcript:

1 Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet  Stephen R. Durham, MD, Waltraud Emminger, MD, Alexander Kapp, MD, Giselda Colombo, MD, Jan G.R. de Monchy, MD, Sabina Rak, MD, Glenis K. Scadding, MD, FRCP, Jens S. Andersen, PhD, Bente Riis, PhD, Ronald Dahl, MD  Journal of Allergy and Clinical Immunology  Volume 125, Issue 1, Pages e7 (January 2010) DOI: /j.jaci Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Overview of trial subjects during the last treatment year (year 3) and the follow-up year (year 4). For a complete trial overview, please refer to this article's Online Repository. FAS, Full analysis set. #Other reasons for withdrawal included “lost to follow-up,” “pregnancy,” “withdrawal of consent,” “subject noncompliance,” or “other.” ∗Four subjects did not provide diary data in year 4 but were allowed to continue in the trial. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 Primary end points over the 4 years of the trial are shown as adjusted mean scores (full analysis set), with the relative differences between treatment groups in percentages and the P value for the differences in adjusted means. The dotted line symbolizes the end of 3 years of treatment. A, Average daily grass pollen count. B, Average rhinoconjunctivitis symptom score. C, Average rhinoconjunctivitis medication score. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Immunologic effects (A, P pratense–specific IgG4; B, IgE-blocking factor) of treatment (change from baseline with 95% CIs for the placebo [open circles] and active [solid circles] groups). The subjects received, on average, 34 months of treatment initiation (dotted line). The grass pollen seasons had onset approximately 8 (2005), 20 (2006), 32 (2007), and 44 (2008) months after treatment initiation. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Overview of trial subjects during the 4 years of the trial
Overview of trial subjects during the 4 years of the trial. FAS, Full analysis set. ∗The treatment set showed no statistically significant difference during the 2005 grass pollen season between subjects continuing and those not continuing in the extension. #Other reasons for withdrawal included “lost to follow-up,” “pregnancy,” “withdrawal of consent,” “subject noncompliance,” or “other.” ¤Four subjects did not provide diary data in year 4 but were allowed to continue in the trial. Journal of Allergy and Clinical Immunology  , e7DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet  Stephen."

Similar presentations

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,

Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy  Ravi S. Swamy, MD, Neha Reshamwala,
Susan L. Limb, MD, Kathryn C. Brown, MD, Robert A. Wood, MD, Robert A

Susan L. Limb, MD, Kathryn C. Brown, MD, Robert A. Wood, MD, Robert A
Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,
Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.
Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.
Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial  Jens U. Ponikau, MD, David.
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy  Harold Nelson, MD, Shannon Cartier, MSc,

Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy  Harold Nelson, MD, Shannon Cartier, MSc,
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Similar presentations

Ads by Google